Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Flucytosine for Cryptococcal Meningitis
NCT06414512Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of flucytosine in cryptococcal meningitis (2 arms), sponsored by University of Minnesota. Primary endpoint: Early Fungicidal Activity at 2 weeks. Started Apr 2024; status: completed.
02
Drugs
flucytosine
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on NCT06414512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414512.